Abstract
To assess the incremental cost-effectiveness (ICER) and cost-utility (ICUR) ratio of polatuzumab vedotin with rituximab and chemotherapy (Pola-R-CHP) versus rituximab and chemotherapy (R-CHOP) for treatment-naïve adult patients with diffuse large B-cell lymphoma (DLBCL), from the Italian Health Service perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
